Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of blinatumomab in adult relapsed/refractory B-precursor acute lymphoblastic leukemia
2011-002257-61Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2011
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoint: CR + CRh rate within two cycles. Started Aug 2011; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2011-002257-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002257-61.